Human leukocyte interferon in therapy of patients with urinary bladder papillomatosis, breast cancer, and melanoma.
The authors report the result of local and parenteral applications of human leukocyte crude interferon in the therapy of eight patients with urinary bladder papillomatosis, four patients with breast cancer, and two patients with melanoma. The doses and effects of treatment are presented in tables. Clinical application of human leukocyte interferon (HLI) to these three types of malignant tumors has yielded encouraging results. The authors believe that investigations on HLI applications to some malignant tumors should continue because the results obtained indicate that interferon possesses not only an antiviral but also an antitumor activity.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010212:Papilloma / Q000473:pathology / Q000628:therapy*; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
D007372:Interferons